Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
265.9
-3.05 (-1.13%)
Market Cap: 34.30 Bil
Enterprise Value: 33.17 Bil
PE Ratio: 0
PB Ratio: 1,063.60
GF Score: 78/100 Alnylam Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021 / 06:30PM GMT
Release Date Price:
$144.28
(+1.61%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
Hi. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome John Maraganore, the CEO of Alnylam. This is a fireside chat format. Thanks for joining us today, John.
John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Pleasure to be here, Maury. Thank you.
Questions & Answers
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
So maybe to start off, if you can provide a 1-minute overview of Alnylam.
John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Yes. Thanks. Alnylam is the pioneering company in RNAi therapeutics. We brought 4 products to the market, 3 that we directly commercialize globally, 1 that we're partnered with Novartis. And all of these medicines, at least in our view, have really been transformative for patients. So we're
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot